Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

PHASE3CompletedINTERVENTIONAL
Enrollment

510

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

September 30, 2001

Study Completion Date

June 30, 2003

Conditions
Vitreous HemorrhageDiabetic Retinopathy
Interventions
DRUG

Placebo

DRUG

Vitrase

Hyaluronidase 55 IU in saline solution

DRUG

Vitrase

Hyaluronidase 75 IU in saline solution

Trial Locations (58)

1105

University of Amsterdam, Amsterdam

1449

Joseph J. Krouse, MB, ChB, Alberton

2000

University of Sydney, Sydney

2088

Royal North Shore Hospital, St Leonards

2145

University of Sydney/Westmead Hospital, Westmead

2195

Louis P. Kruger, MB, ChB, Johannesburg

3002

Royal Victorian Eye and Ear Hospital, East Melbourne

3015

University Hospital Rotterdam, Rotterdam

4001

Addington Hospital, KwaKhangela

4029

Royal Brisbane Hospital, Herston

5000

Royal Adelaide Hospital, Adelaide

5201

Kelvin N. Rivett, MB, ChB, East London

7530

James Acton, MB ChB, Bellville

7708

Newlands Surgical Clinic, Cape Town

7937

Groote Schuur Hospital, Cape Town

9301

Nasionale Hospital, Bloemfontein

9713

Academic Hospital Groningen, Groningen

28006

Hospital de la Princesa, Madrid

28034

Hospital Ramon y Cajal, Madrid

46009

Hospital Universitario La Fe, Valencia

74210-010

Universidade Federal de Goiania, Goiânia

30130-270

Universidade Federal de Minas Gerais, Belo Horizonte

80730-200

Universidade Federal do Parana, Curitiba

90035-003

Universidade Federal do Rio Grande do Sul, Porto Alegre

01525-001

Universidade de Sao Paulo, São Paulo

04023-062

Universidade Federal de Sao Paulo, Escola Paulista e Medicina, São Paulo

H1085

Semmelweiss University, Budapest

H1134

Central Army Hospital of the Hungarian Army, Budapest

H1145

Uzsoki Street Hospital of the Municipality of Capital, Budapest

H4012

Medical University of Debrecen, Debrecen

H7624

Medical University of Pecs, Pécs

H6720

University of Szeged, Albert Szent-Gyorgyi Medical University, Szeged

I-67100

Universita degli Studi dell'Aguila, Coppito

I-50134

Universita degli Studi di Firenze, Florence

I-00161

Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia, Roma

85-168

Klinika Chorob Oczu, Bydgoszcz

41-902

Silesian School of Medicine, Bytom

80-211

Ophtalmology Clinic, Gdansk

90-153

Medical Academy, Lodz, Lodz

20-079

Ophthalmology Chair and Clinic, Lublin

60-479

Main Regional Hospital, Poznan

61-841

K. Marcinkowski University of Medical Sciences, Poznan

03-401

Medical Academy, Warsaw, Warsaw

50-368

Wroclaw University of Medicine, Wroclaw

0002

Pretoria Eye Institute, Pretoria

03015

Instituto Oftalmologico de Alicante, Alicante

LL17 0RS

H. M. Stanley Hospital, St Asaph

BN2 5BF

Sussex Eye Hospital, Brighton

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

EH3 9HA

Royal Infirmary of Edinburgh, Edinburgh

RH1 5RH

East Surrey Hospital, Redhill

BS1 2LX

Bristol Eye Hospital, Bristol

HU3 2JZ

Hull Royal Infirmary, Hull

L7 8XP

Royal Liverpool University Hospital, Liverpool

SE1 7EH

St. Thomas' Hospital, London

SE5 9RS

Kings College Hospital, London

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

OX2 6HE

Oxford Eye Hospital, Oxford

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00198497 - Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage | Biotech Hunter | Biotech Hunter